We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Pharmacokinetics of REGN2810 (Cemiplimab) Anti-programmed Death-ligand 1 (Anti-PD-1) in Japanese Adult Patients With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03233139
Recruitment Status : Recruiting
First Posted : July 28, 2017
Last Update Posted : September 1, 2022
Information provided by (Responsible Party):
Regeneron Pharmaceuticals